MA53020A - Protéine de fusion du fviii améliorée et utilisation associée - Google Patents

Protéine de fusion du fviii améliorée et utilisation associée

Info

Publication number
MA53020A
MA53020A MA053020A MA53020A MA53020A MA 53020 A MA53020 A MA 53020A MA 053020 A MA053020 A MA 053020A MA 53020 A MA53020 A MA 53020A MA 53020 A MA53020 A MA 53020A
Authority
MA
Morocco
Prior art keywords
fusion protein
associated use
fviii fusion
enhanced fviii
enhanced
Prior art date
Application number
MA053020A
Other languages
English (en)
French (fr)
Inventor
Xian Chen
Jie Gao
Haitao Hu
Lingli Huang
Xiang Li
Bin Liu
Zijia Ren
Hongsheng Su
Qilei Wang
Shuang Wang
Shuya Wang
Wenwen Wang
Xiaoshan Wang
Yali Wang
Chunfeng Xiao
Lili Zhang
Luyan Zhu
Original Assignee
Zhengzhou Gensciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou Gensciences Inc filed Critical Zhengzhou Gensciences Inc
Publication of MA53020A publication Critical patent/MA53020A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA053020A 2018-05-18 2019-05-16 Protéine de fusion du fviii améliorée et utilisation associée MA53020A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810481941 2018-05-18

Publications (1)

Publication Number Publication Date
MA53020A true MA53020A (fr) 2021-05-05

Family

ID=68539524

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053020A MA53020A (fr) 2018-05-18 2019-05-16 Protéine de fusion du fviii améliorée et utilisation associée

Country Status (9)

Country Link
US (1) US12440572B2 (enExample)
EP (1) EP3816181A4 (enExample)
JP (2) JP2021530437A (enExample)
KR (1) KR102575788B1 (enExample)
CN (2) CN113039200B (enExample)
BR (1) BR112020023168A2 (enExample)
MA (1) MA53020A (enExample)
MX (1) MX2020012103A (enExample)
WO (1) WO2019219049A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4534563A1 (en) 2022-05-25 2025-04-09 Jiangsu Gensciences Inc. Fviii fusion protein conjugate having extended half-life and use thereof
CN116284411B (zh) * 2023-02-03 2024-02-13 北京基科晟斯医药科技有限公司 抗培重组人凝血因子VIII-Fc融合蛋白的抗体及其应用
CN116036244B (zh) * 2023-02-24 2023-09-19 北京基科晟斯医药科技有限公司 培重组人凝血因子VIII-Fc融合蛋白用于治疗含抑制物的血友病A的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818679A (en) 1985-02-19 1989-04-04 The Trustees Of Columbia University In The City Of New York Method for recovering mutant cells
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
EP1003894A2 (en) * 1997-07-18 2000-05-31 Chiron Corporation Lentiviral vectors
SI1824988T1 (sl) 2004-11-12 2017-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
EP1891231A4 (en) 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US20120121613A1 (en) 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
EP2536754A1 (en) * 2010-02-16 2012-12-26 Novo Nordisk A/S Factor viii fusion protein
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
HK1198541A1 (en) 2011-10-18 2015-05-15 Csl Limited Method for improving the stability of purified factor viii after reconstitution
CN103172745A (zh) 2011-12-21 2013-06-26 北京韩美药品有限公司 包含免疫球蛋白Fc片段的长效人内皮抑素
EA035323B1 (ru) 2012-01-12 2020-05-28 Биовератив Терапьютикс Инк. Полипептиды химерного фактора viii и их применение
WO2014008480A2 (en) * 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
CN104519912A (zh) 2012-08-13 2015-04-15 诺和诺德A/S（股份有限公司） 液体因子viii制剂
WO2014100913A1 (en) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
CN103539860B (zh) 2013-11-01 2014-12-03 广州优联康医药科技有限公司 一种长效重组人促卵泡激素融合蛋白
SG11201805497QA (en) * 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
JP6877469B2 (ja) 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途

Also Published As

Publication number Publication date
CN113039200B (zh) 2023-07-25
MX2020012103A (es) 2021-01-29
KR20210005248A (ko) 2021-01-13
BR112020023168A2 (pt) 2021-02-09
JP2023093634A (ja) 2023-07-04
EP3816181A4 (en) 2022-04-20
CN117467019A (zh) 2024-01-30
KR102575788B1 (ko) 2023-09-08
EP3816181A1 (en) 2021-05-05
JP7492780B2 (ja) 2024-05-30
CN113039200A (zh) 2021-06-25
US12440572B2 (en) 2025-10-14
US20210361775A1 (en) 2021-11-25
WO2019219049A1 (zh) 2019-11-21
JP2021530437A (ja) 2021-11-11

Similar Documents

Publication Publication Date Title
IL279897A (en) Fusosome compositions and uses thereof
KR102201086B9 (ko) Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
EP3442579A4 (en) ANTI-HUMAN-VISTA ANTIBODIES AND USE THEREOF
IL268780A (en) Pd-l1 variant immunomodulatory proteins and uses thereof
EP3680331A4 (en) Modified cas9 protein, and use thereof
EP3820887A4 (en) Pd1-4-1bbl variant fusion protein and methods of use thereof
MA44993A (fr) Polypeptides de fusion cd40l-fc et procédés d'utilisation associés
EP3523332A4 (en) ANTI-HUMAN 4-1 BB ANTIBODY AND ITS USE
IL262652A (en) Gdf15 fusion proteins and uses thereof
EP3430058A4 (en) MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
IL254165A0 (en) Immunomodulatory fusion proteins and uses thereof
EP3810172A4 (en) Heterodimeric proteins and uses thereof
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
EP3882277A4 (en) FUSION PROTEIN AND USE THEREOF
EP3778665A4 (en) POLYETHYLENE AND CHLORINATED POLYETHYLENE THEREOF
IL280631A (en) Novel crispr-associated protein and use thereof
IL283942A (en) Tubulysins and protein-tubulysin conjugates
SG11202110400QA (en) Fusion protein and use thereof
EP3722305A4 (en) HM-3 FUSION PROTEIN AND ITS USE
EP3770187A4 (en) POLYETHYLENE AND CHLORINATED POLYETHYLENE THEREOF
EP3778664A4 (en) POLYETHYLENE AND CHLORINATED POLYETHYLENE THEREOF
MA44777A (fr) Anticorps humanisés anti-basigine et leur utilisation
EP3387019A4 (en) RELAXIN IMMUNOGLOBULIN FUSION PROTEINS AND METHOD OF USE
DK3737402T5 (da) Modificeret protein
EP3428147A4 (en) Polyethylene glycol derivative and use thereof